New combo therapy aims to keep lymphoma in check after transplant
NCT ID NCT04491370
First seen Apr 22, 2026 · Last updated May 20, 2026 · Updated 5 times
Summary
This study is for people with certain types of B-cell or Hodgkin lymphoma. Participants first get a stem cell transplant using their own cells, then receive a targeted drug called polatuzumab vedotin every 3 weeks for up to 8 doses. The goal is to see if this approach is safe and helps control the disease longer. About 20 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New York Medical Center
RECRUITINGValhalla, New York, 10595, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.